Odaily Planet Daily News: UBS Group said it has raised its target price for Moderna (MRNA.O) from $50 to $150. Previously reported: Moderna’s personalized mRNA cancer vaccine, developed in collaboration with Merck & Co., achieved a major success in Phase 3 clinical trials targeting high-risk melanoma. It was the first mRNA cancer therapy to demonstrate efficacy in large-scale Phase 3 trials. After the news was released, Moderna’s share price surged nearly 177% in a single day.